Aprea Therapeutics to Provide Clinical Update on ACESOT-1051 Phase 1 Trial Evaluating WEE1 Inhibitor, APR-1051, at ASCO 2026 Annual Meeting
Rhea-AI Summary
Aprea Therapeutics (Nasdaq: APRE) announced acceptance of an abstract reporting early results from the first-in-human Phase 1 ACESOT-1051 study of WEE1 inhibitor APR-1051 for advanced solid tumors at the ASCO 2026 Annual Meeting, May 29–June 2, 2026 in Chicago.
The poster presentation (Board 244) is scheduled for May 30, 2026, 1:30 PM–4:30 PM CDT, with presenting author Shiraj Sen, MD, PhD. Trial identifier: ClinicalTrials.gov NCT06260514.
AI-generated analysis. Not financial advice.
Positive
- None.
Negative
- None.
News Market Reaction – APRE
On the day this news was published, APRE declined 7.51%, reflecting a notable negative market reaction. Argus tracked a trough of -12.9% from its starting point during tracking. Our momentum scanner triggered 6 alerts that day, indicating moderate trading interest and price volatility. This price movement removed approximately $976K from the company's valuation, bringing the market cap to $12.03M at that time.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Market Reality Check
Peers on Argus
APRE is down 1.9% while sector peers show mixed moves: CYCCP at -5.61%, AEON, INAB, KPRX, and RNAZ up between 1.02% and 4.9%. Momentum scanner only flags CLDI up 4.24% with no news, supporting a stock-specific context for APRE.
Previous Clinical trial Reports
| Date | Event | Sentiment | Move | Catalyst |
|---|---|---|---|---|
| Mar 30 | Clinical response data | Positive | +8.2% | Reported confirmed partial response and stable disease in ACESOT-1051 trial. |
| Oct 15 | Dose selection update | Positive | -1.3% | Set ATRN-119 RP2D and signaled focus on combination strategies. |
| Jun 25 | Early efficacy signals | Positive | +10.1% | Presented antiproliferative data and early stable disease in APR-1051 trial. |
| Dec 11 | Dosing strategy change | Positive | +3.3% | Initiated BID dosing for ATRN-119 to potentially optimize outcomes. |
| Oct 09 | Clinical leadership move | Positive | -1.6% | Engaged senior medical advisor to lead WEE1 clinical development. |
Clinical trial updates for APRE have more often produced positive price moves, but with notable instances of negative reactions despite seemingly constructive clinical progress.
Over the past two years, APRE’s news flow has centered on its DDR-targeted pipeline, particularly WEE1 inhibitor APR-1051 and ATR inhibitor ATRN-119. Clinical-trial updates have included BID dosing changes, establishment of an 1,100 mg RP2D for ATRN-119, and emerging responses and disease stabilization for APR-1051. These updates often coincided with sizeable price swings, underscoring the stock’s sensitivity to clinical milestones similar to today’s ASCO-focused update.
Historical Comparison
In the past 5 clinical-trial updates, APRE’s average move was 3.73%, with both strong rallies and occasional selloffs. An ASCO-focused Phase 1 update for APR-1051 fits this pattern of meaningful, but directionally variable, reactions.
Clinical news shows progression from early APR-1051 signals and ATRN-119 dose exploration to confirmed responses and now formal data sharing at major oncology meetings like ASCO.
Regulatory & Risk Context
APRE has an active S-3/A shelf dated Mar 17, 2026, noted as effective, with at least one related usage via a 424B3 prospectus on Mar 19, 2026. The amendment only updated the auditor consent and did not change prospectus terms.
Market Pulse Summary
The stock moved -7.5% in the session following this news. A negative reaction despite an ASCO 2026 clinical update would fit prior instances where positive-sounding trial news coincided with selloffs. The market may focus on financing overhang from recent private placements and resale registration rather than the APR-1051 Phase 1 details. With an effective shelf and reverse-split authorization under consideration, concerns about future equity structure could also pressure sentiment.
Key Terms
wee1 inhibitor medical
phase 1 medical
clinicaltrials.gov regulatory
AI-generated analysis. Not financial advice.
DOYLESTOWN, Pa., April 21, 2026 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (Nasdaq: APRE) (“Aprea”, or the “Company”), a clinical-stage precision medicine oncology company focused on the discovery and development of targeted therapies for patients with biomarker-defined cancers, today announced the acceptance of an abstract “Early results from the first-in-human phase 1 study of WEE1 inhibitor APR-1051 in patients with advanced solid tumors (ACESOT-1051)” at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting, to take place May 29 - June 2, 2026, in Chicago, IL.
| Presentation Details: | |
| Title: | Early results from the first-in-human phase 1 study of WEE1 inhibitor APR-1051 in patients with advanced solid tumors (ACESOT-1051) |
| Presenting author: | Shiraj Sen, MD. PhD., NEXT Oncology Dallas, TX |
| Session: | Poster Session - Developmental Therapeutics—Molecularly Targeted Agents and Tumor Biology |
| Date and Time: | May 30, 2026, 1:30 PM-4:30 PM CDT |
| Poster Board: | 244 |
For more information on the ACESOT-1051 trial, refer to ClinicalTrials.gov NCT06260514.
About Aprea
Aprea is a clinical-stage precision medicine oncology company focused on the discovery and development of targeted therapies for patients with biomarker-defined cancers. The Company is pioneering a new approach to treat cancer by exploiting vulnerabilities associated with cancer cell mutations. This approach was developed to kill tumors while minimizing the effect on normal, healthy cells. Aprea’s technology has potential applications across multiple cancer types, enabling it to target a range of tumors, including ovarian, endometrial, colorectal and head and neck squamous cell carcinoma. The company’s lead programs are APR-1051, an oral, small-molecule inhibitor of WEE1 kinase, and ATRN-119, a small molecule ATR inhibitor, both in clinical development for solid tumor indications. For more information, please visit the company website at www.aprea.com.
The Company may use, and intends to use, its investor relations website at https://ir.aprea.com/ as a means of disclosing material nonpublic information and for complying with its disclosure obligations under Regulation FD.
Forward-Looking Statement
Certain information contained in this press release includes “forward-looking statements”, within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended related to our study analyses, clinical trials, regulatory submissions, and projected cash position. We may, in some cases use terms such as “future,” “predicts,” “believes,” “potential,” “continue,” “anticipates,” “estimates,” “expects,” “plans,” “intends,” “targeting,” “confidence,” “may,” “could,” “might,” “likely,” “will,” “should” or other words that convey uncertainty of the future events or outcomes to identify these forward-looking statements. Our forward-looking statements are based on current beliefs and expectations of our management team and on information currently available to management that involve risks, potential changes in circumstances, assumptions, and uncertainties. All statements contained in this press release other than statements of historical fact are forward-looking statements, including statements regarding our ability to develop, commercialize, and achieve market acceptance of our current and planned products and services, our research and development efforts, including timing considerations and other matters regarding our business strategies, use of capital, results of operations and financial position, and plans and objectives for future operations. Any or all of the forward-looking statements may turn out to be wrong or be affected by inaccurate assumptions we might make or by known or unknown risks and uncertainties. These forward-looking statements are subject to risks and uncertainties including, without limitation, risks related to the success, timing, and cost of our ongoing clinical trials and anticipated clinical trials for our current product candidates, including statements regarding the timing of initiation, pace of enrollment and completion of the trials (including our ability to fully fund our disclosed clinical trials, which assumes no material changes to our currently projected expenses), futility analyses, presentations at conferences and data reported in an abstract, and receipt of interim or preliminary results (including, without limitation, any preclinical results or data), which are not necessarily indicative of the final results of our ongoing clinical trials, our understanding of product candidates mechanisms of action and interpretation of preclinical and early clinical results from its clinical development programs, and our ability to predict clinical outcomes based on such preclinical and early clinical results, our ability to continue as a going concern, and the other risks, uncertainties, and other factors described under “Risk Factors,” “Management’s Discussion and Analysis of Financial Condition and Results of Operations” and elsewhere in the documents we file with the U.S. Securities and Exchange Commission. For all these reasons, actual results and developments could be materially different from those expressed in or implied by our forward-looking statements. You are cautioned not to place undue reliance on these forward-looking statements, which are made only as of the date of this press release. We undertake no obligation to update such forward-looking statements for any reason, except as required by law.
Investor Contact:
Mike Moyer
LifeSci Advisors
mmoyer@lifesciadvisors.com
